We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Management of Metastatic Breast Cancer in Clinical Practice - Retrospective Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01715155
First Posted: October 26, 2012
Last Update Posted: August 22, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
October 22, 2012
October 26, 2012
August 22, 2013
December 2012
June 2013   (Final data collection date for primary outcome measure)
Number of progression events on a per patient-year-basis [ Time Frame: Up to 2 years 5 months ]
Same as current
Complete list of historical versions of study NCT01715155 on ClinicalTrials.gov Archive Site
  • Proportion of patients among study population who have not progressed at 12 and 18 months after they were diagnosed [ Time Frame: Up to 2 years 5 months ]
  • Median and mean time interval that elapsed between diagnosis and first objective tumor progression (TTP) event and subsequent events [ Time Frame: Up to 2 years 5 months ]
  • Median and mean time from the date of diagnosis to the date of breast cancer progression or death whichever occurred first [ Time Frame: Up to 2 years 5 months ]
Same as current
Not Provided
Not Provided
 
Management of Metastatic Breast Cancer in Clinical Practice - Retrospective Study
A Retrospective Cohort Study on Therapeutic Management of Metastatic Breast Cancer in Clinical Practice in Bulgaria
The purpose of this study is to evaluate the incidence rate of progression of disease, to describe the diagnostic and clinical management in patients with Metastatic Breast Cancer in the clinical practice in Bulgaria.
A Retrospective Cohort Study on Therapeutic Management of Metastatic Breast Cancer in Clinical Practice in Bulgaria
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample
Patients newly diagnosed with breast cancer (according to ICD-10) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a non-metastatic stage.
Metastatic Breast Cancer
Not Provided
Female patients diagnosed with metastatic breast cancer
Patients newly diagnosed with metastatic breast cancer, either De Novo or having progressed from a non-metastatic stage.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
171
June 2013
June 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • New diagnosis of breast cancer according to ICD-10 with confirmed metastasis
  • Confirmed diagnosis between 1st July 2010 and 30th June 2011.
  • Female patient managed for her disease at the same setting where final diagnosis of MBC was performed.

Exclusion Criteria:

  • History of concurrent or other primary malignancies (except curatively resected non-melanoma skin cancer or in situ cervical cancer).
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Bulgaria
 
 
NCT01715155
NIS-OBG-XXX-2012/1
No
Not Provided
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Not Provided
AstraZeneca
August 2013